Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma

Author:

Cai Qingqing12,Chen Yiming2,Zou Dehui3,Zhang Liang2,Badillo Maria2,Zhou Shouhao4,Lopez Elyse2,Jiang Wenqi1,Huang Huiqiang1,Lin Tongyu1,Romaguera Jorge2,Wang Michael25

Affiliation:

1. Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

2. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

3. Lymphoma and Myeloma Center, Institute of Hematology and Blood Diseases Hospital, State Key Lab of Experimental Methods of Hematology, Chinese Academy of Medical Sciences and Peking Union of Medical College, Tianjin, China

4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

5. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3